American Society of Clinical OncologyTBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Olaparib, a PARP inhibitor, is approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. Find out whether the results from this latest report will emphasize the value of molecular characterization (homologous recombination (HR)–related genes other than BRCA1/2) for treatment decisions in MBC.

American Society of Clinical OncologyPlaying with Dynamite? A Cautious Assessment of TNT

In this article from the Journal of Clinical Oncology, the authors suggest the need for caution and well-conducted trials to systematically address the question of total neoadjuvant therapy (TNT) in rectal cancer, which can lead to overtreatment and unnecessary toxicity without a proven benefit. Despite some of its theoretical advantages, declaring TNT a new standard […]

American Medical AssociationAssociation of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer

In this Original Investigation from JAMA Oncology, the authors attempt to discover whether increased coffee consumption is associated with improved survival in patients with advanced or metastatic colorectal cancer. Overall survival (OS) and progression-free survival (PFS) were the main outcomes and measures, and both decaffeinated and caffeinated coffee were studied.